Firm targeting potential bacterial role in Alzheimer's gets $76 million Series B

Retrieved on: 2018-05-30 23:45:00

Tags for this article:

Click the tags to see associated articles and topics

Firm targeting potential bacterial role in Alzheimer's gets $76 million Series B. View article details on hiswai:

Excerpt

<div>... Series B round from a pool of new investors including <b>Sequoia Capital</b>, Vulcan Capital, Verily Life Sciences, EPIQ Capital Group, RSL Investments, ...</div>

Article found on:

View Original Article